Women’s Health Breakthroughs: Migraine, Fibromyalgia, Postpartum Depression and More
🚺 This week’s Women’s Health Updates by LucidQuest brings you the latest FDA approvals, clinical trial results, and research breakthroughs that impact women’s health, including key developments in neurology, psychiatry, and hematology.
This episode covers:
💊 Migraine treatments: Lundbeck’s Vyepti sales surge with a 54 percent increase, now projected to exceed one point one billion dollars in U.S. peak sales.
🧠 Mental health research: Despite a negative FDA advisory vote, Lundbeck remains positive about Rexulti for PTSD.
🧩 Fibromyalgia breakthrough: FDA approves Tonmya, the first new therapy for the condition in over 15 years.
🧬 Immunotherapy milestone: PAPZIMEOS becomes the first FDA-approved treatment for recurrent respiratory papillomatosis.
💉 Iron deficiency anemia: Generics of Venofer enter the U.S. market after FDA clearance.
🤱 Postpartum depression: Reunion’s psychedelic drug RE104 shows lasting benefits in Phase 2.
🩸 Setbacks in hematology: Pfizer’s inclacumab trial fails in sickle cell disease
💊Biohaven ends OCD program for troriluzole.
🌈 Depression research: BH-200 shows promising precision psychiatry results in Phase 2b trial.
📢 Stay Ahead in Women’s Health Research!
✅ Like, share, and subscribe for weekly updates on women’s health, neurology, and innovative therapies.
#WomensHealth #Fibromyalgia #Migraine #PostpartumDepression #Hematology #SickleCellDisease #LucidQuest